** Drug developer Protagonist Therapeutics' PTGX.O shares rise 30.4% to $50.02
** PTGX says the mid-stage study of all three doses of once-daily experimental drug, icotrokinra, conducted by its collaboration partner Johnson & Johnson JNJ.N met its main goal in patients with ulcerative colitis
** Ulcerative colitis, a form of inflammatory bowel disease $(IBD)$, is a condition in which the lining of the large intestine (colon) and rectum become inflamed
** Co says the study showed significant improvements over placebo in clinical recovery, symptom relief, and showed reduction in signs of disease severity within 12 weeks
** Co says the study achieved a response rate of 63.5% vs 27% for placebo
** PTGX had risen 24.2% in the past 12 months, as of last close
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。